PDS Biotechnology is a clinical stage Biopharmaceutical Company developing the next-generation of simpler, safer and more effective treatments and preventions for cancer and chronic infectious diseases.
To see how Versamune™ works, please click here.
Stimulating the immune system has been demonstrated to be one of the most promising approaches to treating cancer and several debilitating and chronic infectious diseases such as hepatitis and HIV.
PDS Biotechnology has developed a simple and synthetic nanoparticle platform vector known as Versamune®. This novel and superior cancer and vaccine nanotechnology platform is very effective in training the immune system to recognize and fight the particular disease (see video on how Versamune® works). To do so, a unique protein from the particular cancer type or virus is formulated and injected with Versamune®. In pre-clinical studies very effective and superior treatment of advanced aggressive cancers with low doses of the Versamune®-based products has been demonstrated. The preclinical studies also demonstrated that the Versamune®-based products are exceptionally safe and well tolerated. Versamune® is the first synthetic immunotherapy and vaccine vector to demonstrate potent disease killing T-cell responses without the need for the addition of immune activators known as adjuvants.
PDS Biotechnology is initially applying the Versamune® vector to the treatment of HPV related cancers such as cervical cancer, oral cancer and cervical intraepithelial neoplasia (pre-cervical cancer). PDS’s lead HPV cancer immunotherapy product, PDS0101 is currently in phase 1 human clinical trials at multiple clinics within the US.
PDS Biotechnology has also demonstrated superior efficacy with a novel and rapid acting Versamune®-based preventive pandemic influenza vaccine.
In 2012, PDS signed a licensing agreement with a global pharmaceutical company, Merck KGaA, granting it a license to utilize PDS Biotechnology’s Versamune® vector in the development of two new cancer immunotherapies.